Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape

SIMPLE SUMMARY: PARP inhibitors (PARPi) are current treatment options for patients with ovarian, breast, pancreatic or prostate cancer. Although PARPi have transformed the patient journey in these disease settings, resistance eventually develops, leaving them with limited therapeutic opportunities....

Descripción completa

Detalles Bibliográficos
Autores principales: Prados-Carvajal, Rosario, Irving, Elsa, Lukashchuk, Natalia, Forment, Josep V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750220/
https://www.ncbi.nlm.nih.gov/pubmed/35008208
http://dx.doi.org/10.3390/cancers14010044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750220/
https://www.ncbi.nlm.nih.gov/pubmed/35008208
http://dx.doi.org/10.3390/cancers14010044

Ejemplares similares